TEVA PHARMACEUTICAL-SP ADR (TEVA) Fundamental Analysis & Valuation

NYSE:TEVA • US8816242098

31.05 USD
-0.7 (-2.2%)
At close: Mar 6, 2026
30.6 USD
-0.45 (-1.45%)
Pre-Market: 3/9/2026, 4:21:21 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This TEVA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

5

Overall TEVA gets a fundamental rating of 5 out of 10. We evaluated TEVA against 193 industry peers in the Pharmaceuticals industry. While TEVA has a great profitability rating, there are quite some concerns on its financial health. TEVA scores decently on growth, while it is valued quite cheap. This could make an interesting combination.


Dividend Valuation Growth Profitability Health

8

1. TEVA Profitability Analysis

1.1 Basic Checks

  • In the past year TEVA was profitable.
  • In the past year TEVA had a positive cash flow from operations.
  • In multiple years TEVA reported negative net income over the last 5 years.
  • Each year in the past 5 years TEVA had a positive operating cash flow.
TEVA Yearly Net Income VS EBIT VS OCF VS FCFTEVA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -5B -10B -15B

1.2 Ratios

  • TEVA's Return On Assets of 3.46% is amongst the best of the industry. TEVA outperforms 84.46% of its industry peers.
  • Looking at the Return On Equity, with a value of 17.81%, TEVA belongs to the top of the industry, outperforming 89.64% of the companies in the same industry.
  • Looking at the Return On Invested Capital, with a value of 12.03%, TEVA belongs to the top of the industry, outperforming 91.19% of the companies in the same industry.
  • The Average Return On Invested Capital over the past 3 years for TEVA is below the industry average of 13.08%.
  • The last Return On Invested Capital (12.03%) for TEVA is above the 3 year average (10.53%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 3.46%
ROE 17.81%
ROIC 12.03%
ROA(3y)-0.66%
ROA(5y)-1.34%
ROE(3y)-6.71%
ROE(5y)-9.48%
ROIC(3y)10.53%
ROIC(5y)9.34%
TEVA Yearly ROA, ROE, ROICTEVA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -20 -40 -60 -80

1.3 Margins

  • Looking at the Profit Margin, with a value of 8.16%, TEVA belongs to the top of the industry, outperforming 84.46% of the companies in the same industry.
  • With an excellent Operating Margin value of 24.09%, TEVA belongs to the best of the industry, outperforming 91.71% of the companies in the same industry.
  • TEVA's Operating Margin has improved in the last couple of years.
  • TEVA has a better Gross Margin (52.72%) than 66.32% of its industry peers.
  • TEVA's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 24.09%
PM (TTM) 8.16%
GM 52.72%
OM growth 3Y3.96%
OM growth 5Y4.75%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.99%
GM growth 5Y2.49%
TEVA Yearly Profit, Operating, Gross MarginsTEVA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 -40 -60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. TEVA Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so TEVA is still creating some value.
  • The number of shares outstanding for TEVA has been increased compared to 1 year ago.
  • The number of shares outstanding for TEVA has been increased compared to 5 years ago.
  • The debt/assets ratio for TEVA has been reduced compared to a year ago.
TEVA Yearly Shares OutstandingTEVA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B
TEVA Yearly Total Debt VS Total AssetsTEVA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20B 40B 60B 80B

2.2 Solvency

  • TEVA has an Altman-Z score of 0.95. This is a bad value and indicates that TEVA is not financially healthy and even has some risk of bankruptcy.
  • With a Altman-Z score value of 0.95, TEVA perfoms like the industry average, outperforming 55.44% of the companies in the same industry.
  • The Debt to FCF ratio of TEVA is 14.64, which is on the high side as it means it would take TEVA, 14.64 years of fcf income to pay off all of its debts.
  • With a decent Debt to FCF ratio value of 14.64, TEVA is doing good in the industry, outperforming 76.68% of the companies in the same industry.
  • TEVA has a Debt/Equity ratio of 1.90. This is a high value indicating a heavy dependency on external financing.
  • TEVA has a worse Debt to Equity ratio (1.90) than 76.17% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.9
Debt/FCF 14.64
Altman-Z 0.95
ROIC/WACC1.45
WACC8.31%
TEVA Yearly LT Debt VS Equity VS FCFTEVA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10B 20B 30B

2.3 Liquidity

  • A Current Ratio of 1.04 indicates that TEVA should not have too much problems paying its short term obligations.
  • TEVA has a worse Current ratio (1.04) than 81.35% of its industry peers.
  • TEVA has a Quick Ratio of 1.04. This is a bad value and indicates that TEVA is not financially healthy enough and could expect problems in meeting its short term obligations.
  • TEVA has a Quick ratio of 0.80. This is amonst the worse of the industry: TEVA underperforms 80.83% of its industry peers.
Industry RankSector Rank
Current Ratio 1.04
Quick Ratio 0.8
TEVA Yearly Current Assets VS Current LiabilitesTEVA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. TEVA Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an nice 17.27% over the past year.
  • The Earnings Per Share has been growing slightly by 4.89% on average over the past years.
  • TEVA shows a small growth in Revenue. In the last year, the Revenue has grown by 4.32%.
  • TEVA shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 0.71% yearly.
EPS 1Y (TTM)17.27%
EPS 3Y4.89%
EPS 5YN/A
EPS Q2Q%35.21%
Revenue 1Y (TTM)4.32%
Revenue growth 3Y4.96%
Revenue growth 5Y0.71%
Sales Q2Q%11.4%

3.2 Future

  • The Earnings Per Share is expected to grow by 6.00% on average over the next years.
  • TEVA is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 1.80% yearly.
EPS Next Y-5.45%
EPS Next 2Y2.99%
EPS Next 3Y6%
EPS Next 5YN/A
Revenue Next Year-0.99%
Revenue Next 2Y0.75%
Revenue Next 3Y1.8%
Revenue Next 5YN/A

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
TEVA Yearly Revenue VS EstimatesTEVA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 5B 10B 15B 20B
TEVA Yearly EPS VS EstimatesTEVA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2020 2021 2022 2023 2024 2025 2026 2027 2028 1 2 3 4 5

More info and screens

Find the best growth stocksShow best growing peers

8

4. TEVA Valuation Analysis

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 10.42 indicates a reasonable valuation of TEVA.
  • TEVA's Price/Earnings ratio is rather cheap when compared to the industry. TEVA is cheaper than 90.16% of the companies in the same industry.
  • The average S&P500 Price/Earnings ratio is at 26.29. TEVA is valued rather cheaply when compared to this.
  • The Price/Forward Earnings ratio is 11.04, which indicates a very decent valuation of TEVA.
  • 87.05% of the companies in the same industry are more expensive than TEVA, based on the Price/Forward Earnings ratio.
  • The average S&P500 Price/Forward Earnings ratio is at 24.60. TEVA is valued rather cheaply when compared to this.
Industry RankSector Rank
PE 10.42
Fwd PE 11.04
TEVA Price Earnings VS Forward Price EarningsTEVA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, TEVA is valued cheaper than 89.64% of the companies in the same industry.
  • TEVA's Price/Free Cash Flow ratio is rather cheap when compared to the industry. TEVA is cheaper than 81.87% of the companies in the same industry.
Industry RankSector Rank
P/FCF 31.11
EV/EBITDA 9.48
TEVA Per share dataTEVA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 -10 15

4.3 Compensation for Growth

  • The excellent profitability rating of TEVA may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y2.99%
EPS Next 3Y6%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. TEVA Dividend Analysis

5.1 Amount

  • No dividends for TEVA!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

TEVA Fundamentals: All Metrics, Ratios and Statistics

TEVA PHARMACEUTICAL-SP ADR

NYSE:TEVA (3/6/2026, 8:04:00 PM)

Premarket: 30.6 -0.45 (-1.45%)

31.05

-0.7 (-2.2%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)01-28
Earnings (Next)05-05
Inst Owners20.99%
Inst Owner Change5.51%
Ins Owners0.45%
Ins Owner Change13.48%
Market Cap35.71B
Revenue(TTM)17.26B
Net Income(TTM)1.41B
Analysts82.86
Price Target0.11 (-99.65%)
Short Float %3.25%
Short Ratio4
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)27.53%
Min EPS beat(2)16.51%
Max EPS beat(2)38.54%
EPS beat(4)4
Avg EPS beat(4)16.39%
Min EPS beat(4)4.65%
Max EPS beat(4)38.54%
EPS beat(8)7
Avg EPS beat(8)8.31%
EPS beat(12)9
Avg EPS beat(12)5.55%
EPS beat(16)10
Avg EPS beat(16)3.14%
Revenue beat(2)2
Avg Revenue beat(2)3.32%
Min Revenue beat(2)0.9%
Max Revenue beat(2)5.75%
Revenue beat(4)2
Avg Revenue beat(4)-0.7%
Min Revenue beat(4)-4.77%
Max Revenue beat(4)5.75%
Revenue beat(8)5
Avg Revenue beat(8)0.11%
Revenue beat(12)8
Avg Revenue beat(12)1.11%
Revenue beat(16)8
Avg Revenue beat(16)-0.59%
PT rev (1m)-1.91%
PT rev (3m)65.29%
EPS NQ rev (1m)-0.34%
EPS NQ rev (3m)-8.04%
EPS NY rev (1m)-1.26%
EPS NY rev (3m)-0.78%
Revenue NQ rev (1m)-0.64%
Revenue NQ rev (3m)-4.37%
Revenue NY rev (1m)-1.5%
Revenue NY rev (3m)-1.76%
Valuation
Industry RankSector Rank
PE 10.42
Fwd PE 11.04
P/S 2.07
P/FCF 31.11
P/OCF 21.66
P/B 4.51
P/tB N/A
EV/EBITDA 9.48
EPS(TTM)2.98
EY9.6%
EPS(NY)2.81
Fwd EY9.06%
FCF(TTM)1
FCFY3.21%
OCF(TTM)1.43
OCFY4.62%
SpS15.01
BVpS6.88
TBVpS-10.32
PEG (NY)N/A
PEG (5Y)N/A
Graham Number21.47
Profitability
Industry RankSector Rank
ROA 3.46%
ROE 17.81%
ROCE 15.24%
ROIC 12.03%
ROICexc 13.83%
ROICexgc 82.57%
OM 24.09%
PM (TTM) 8.16%
GM 52.72%
FCFM 6.65%
ROA(3y)-0.66%
ROA(5y)-1.34%
ROE(3y)-6.71%
ROE(5y)-9.48%
ROIC(3y)10.53%
ROIC(5y)9.34%
ROICexc(3y)11.98%
ROICexc(5y)10.44%
ROICexgc(3y)70.07%
ROICexgc(5y)58.35%
ROCE(3y)13.34%
ROCE(5y)11.83%
ROICexgc growth 3Y24.16%
ROICexgc growth 5Y15.53%
ROICexc growth 3Y17.63%
ROICexc growth 5Y14.52%
OM growth 3Y3.96%
OM growth 5Y4.75%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.99%
GM growth 5Y2.49%
F-Score8
Asset Turnover0.42
Health
Industry RankSector Rank
Debt/Equity 1.9
Debt/FCF 14.64
Debt/EBITDA 2.91
Cap/Depr 50%
Cap/Sales 2.9%
Interest Coverage 4.38
Cash Conversion 31.96%
Profit Quality 81.48%
Current Ratio 1.04
Quick Ratio 0.8
Altman-Z 0.95
F-Score8
WACC8.31%
ROIC/WACC1.45
Cap/Depr(3y)47.55%
Cap/Depr(5y)45.36%
Cap/Sales(3y)3.08%
Cap/Sales(5y)3.29%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)17.27%
EPS 3Y4.89%
EPS 5YN/A
EPS Q2Q%35.21%
EPS Next Y-5.45%
EPS Next 2Y2.99%
EPS Next 3Y6%
EPS Next 5YN/A
Revenue 1Y (TTM)4.32%
Revenue growth 3Y4.96%
Revenue growth 5Y0.71%
Sales Q2Q%11.4%
Revenue Next Year-0.99%
Revenue Next 2Y0.75%
Revenue Next 3Y1.8%
Revenue Next 5YN/A
EBIT growth 1Y17.36%
EBIT growth 3Y9.12%
EBIT growth 5Y5.49%
EBIT Next Year16.83%
EBIT Next 3Y11.69%
EBIT Next 5YN/A
FCF growth 1Y53.27%
FCF growth 3Y3.28%
FCF growth 5Y12.47%
OCF growth 1Y32.24%
OCF growth 3Y1.22%
OCF growth 5Y6.28%

TEVA PHARMACEUTICAL-SP ADR / TEVA FAQ

What is the fundamental rating for TEVA stock?

ChartMill assigns a fundamental rating of 5 / 10 to TEVA.


What is the valuation status of TEVA PHARMACEUTICAL-SP ADR (TEVA) stock?

ChartMill assigns a valuation rating of 8 / 10 to TEVA PHARMACEUTICAL-SP ADR (TEVA). This can be considered as Undervalued.


Can you provide the profitability details for TEVA PHARMACEUTICAL-SP ADR?

TEVA PHARMACEUTICAL-SP ADR (TEVA) has a profitability rating of 8 / 10.


What is the valuation of TEVA PHARMACEUTICAL-SP ADR based on its PE and PB ratios?

The Price/Earnings (PE) ratio for TEVA PHARMACEUTICAL-SP ADR (TEVA) is 10.42 and the Price/Book (PB) ratio is 4.51.


What is the earnings growth outlook for TEVA PHARMACEUTICAL-SP ADR?

The Earnings per Share (EPS) of TEVA PHARMACEUTICAL-SP ADR (TEVA) is expected to decline by -5.45% in the next year.